ClinicalTrials.gg
TerminatedNCT00754052Updated Apr 23, 2018Results posted

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

A Phase 3 interventional study of Aricept (donepezil hydrochloride) and Aricept (donepezil hydrochloride) in Down Syndrome and Cognitive Dysfunction, sponsored by Eisai Inc.. Terminated at 2 sites in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Down Syndrome with a site in United States — 48 open to participants now, 56 under way, 4 of them phase 3. Down Syndrome · United States.

Enrollment
116th of 131
8 · median 40
Started
2008
with 6 others
Phase 3
10 of 205
2 open now
Registered
12th of 205
by date

Among the 205 studies in Down Syndrome with a site in United States, this one is the 116th largest by enrollment of the 131 interventional ones that give a count, is one of 7 that started in 2008, is one of 10 in phase 3, and was the 12th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

48 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.

Read the detailed description

The study will be conducted in approximately 75 sites in the US, India, Singapore, South Korea, Mexico and Chile and will include 210 participants to be enrolled.

03

Conditions studied

  • Down Syndrome
  • Cognitive Dysfunction

Keywords

  • Pediatric
  • Down syndrome
  • Downs
  • Cognitive Dysfunction of Down syndrome
04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: Participants 11 to 17 years of age at the screening visit; weight >35 kilograms (kg).
  2. Sex distribution: both males and females.
  3. Vineland-II Adaptive Behavior Scales (VABS-II)/Parent/Caregiver Rating Form (PCRF) receptive sub-domain raw score of >= 25 and expressive sub-domain raw score of >= 61.
  4. Clinical diagnosis of Down syndrome (DS) - participants may have free trisomy 21, Robertsonian translocations, or mosaic DS.
  5. Naive to approved or unapproved cholinesterase inhibitors (Aricept, Exelon, Cognex, Reminyl/Razadyne, metrifonate, physostigmine) is preferred. However, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening and that it was not discontinued for lack of tolerability or efficacy or for the sole purpose of enrolling the participant in the study. The exception to this prior use is that participants who participated in the Phase II study E2020-A001-219 (A2501059) are not eligible.
  6. Participants residing in the community or in facilities that have consistent and reliable caregivers who can provide efficacy information about the participants.
  7. The participants must be expected to complete all procedures scheduled during the Screening and Baseline visits including all efficacy and safety parameters. Participants who are verbal and able to be understood most of the time are preferred, but those who use other forms of communication, signs, symbol boards or devices to supplement his/her communication ability may be enrolled provided they meet the VABS-II/PCRF receptive and expressive score criteria mentioned above.
  8. Participants must have a parent, or other reliable caregiver who agrees to accompany the participant to all clinic visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule.
  9. The parent or caregiver must be a constant and reliable informant with sufficient contact with the participant to have detailed knowledge of the participant's adaptive functioning in order to be able to complete the VABS-II/PCRF accurately. The same individual should complete the form at every visit, if possible.
  10. Participants should be in good general health with no medical conditions that are considered both and unstable.
  11. Clinical laboratory values within normal limits or abnormalities considered not clinically significant by the investigator and sponsor.
  12. Participants with stable Type I (insulin-dependent) or Type II diabetes are eligible provided they are monitored regularly prior to and during the study to ensure adequate glucose control. (Adequacy of control is based on the investigator's judgment, but should be guided primarily by a glycosylated [] \<8.0 at screening; other information, including records of home monitoring and the screening fasting glucose may support this judgment).
  13. Participants with thyroid disease also may be included in the study provided they are euthyroid and stable on treatment for at least 1 month prior to screening.
  14. Participants with a history of seizure disorder are allowed provided that they are on stable treatment for at least 3 months and have not had a seizure within the past 6 months.
  15. Participants should be independent in ambulation or ambulatory aided (i.e., walker or cane, to wheelchair); vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for achieving VABS-II/PCRF minimum receptive raw scores of >= 25 and expressive scores of >= 61 and for cooperating with secondary efficacy evaluations and study examinations.
  16. Females who have begun menstruation and are thus of may be enrolled but must be documented not to be pregnant by serum pregnancy testing at screening. They also must be practicing an effective means of (abstinence, oral contraceptives, hormonal implants in place at least 1 month prior to enrollment, or a double-barrier method), which must be documented, and the participant and caregiver must be counseled in writing of the importance of not becoming pregnant during the trial. A urine pregnancy test will be done at the Week 4 clinic visit and must be negative prior to dispensing any medication; a serum pregnancy test will be repeated at the Week 10 (or Early Termination) clinic visit.

Exclusion criteria

Exclusion Criteria:

  1. Age range: Participants \<11 or >17 years at the screening visit.
  2. Participants with active or conditions that will, in the investigator's judgment, affect absorption, distribution or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers or severe lactose intolerance); controlled celiac disease is allowed.
  3. Participants with a known to piperidine derivatives or cholinesterase inhibitors.
  4. Participants currently receiving cholinesterase inhibitors or who have received them in the 3 months prior to screening or with prior use >3 months prior to screening who stopped for lack of efficacy or tolerability or simply to enroll the participant in this study. Also excluded are participants who participated in the Phase II study E2020-A001-219 (A2501059). In addition, participants may not have taken any other medications (including memantine) within 3 months prior to screening.
  5. Participants without a reliable parent or caregiver (caregiver responsibilities are described in the Inclusion Criteria above), or with parents or caregivers who are unwilling or unable to complete any of the outcome measures and fulfill the requirements of this study.
  6. Participants with clinically significant obstructive pulmonary disease or asthma, untreated or not controlled by treatment within 3 months prior to screening.
  7. Participants with recent (\<= 1 year) or ongoing hematologic/oncologic disorders (mild anemia allowed).
  8. Evidence of active, clinically significant, and unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease.
  9. Participants with a current (DSM-IV) diagnosis of Major Depressive Disorder (MDD) or any current primary psychiatric diagnosis other than DS (as per DSM-IV). Diagnoses that are secondary, such as attention deficit hyperactivity disorder, are allowed.
  10. Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study. Unsuitability includes female participants who have begun menstruation and are thus of , and who are not practicing an effective means of . Female participants who have begun menstruation and are sexually abstinent or who are practicing another effective means of birth control are not excluded but must be counseled in writing along with their caregiver about the importance of not becoming pregnant during the study and must have a negative pregnancy test at screening and pregnancy testing at Weeks 4 and 10.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Aricept (donepezil hydrochloride)

  • Active comparator
    2

    Drug: Aricept (donepezil hydrochloride)

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.

    Also known as: Donepezil hydrochloride

  • All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.

    Also known as: Donepezil hydrochloride

  • DrugPlacebo

    All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Vineland-II Adaptive Behavior Scale (VABS-II) Parent/Caregiver Rating Form (PCRF) Score Using Last Observation Carried Forward (LOCF)

    Mean change from Baseline from Visit 1 (baseline) to Visit 3 (Week 10 or early termination) in VABS-11/PCRF, a sum of the 9 sub-domain v-scores (3 scores for each of the communication, daily living skills, and socialization domains) using last observation carried forward was planned.

    Time frame: Baseline (Day 0) to Visit 3 (Week 10) or at early termination

Secondary outcomes

  1. Mean Change From Baseline in Additional Analyses of the VABS-11/PCRF

    Additional analyses of the VABS-II/PCRF were planned.

    Time frame: Baseline (Day 0) to Visit 3 (Week 10) or early termination

  2. Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER)

    TOVER, a subject performance-based measure of expressive language function was planned.

    Time frame: Baseline (Day 0) to Visit 3 (Week 10) or early termination

  3. Mean Change From Baseline if the Forward Memory and Attention Sustained Sub-tests of the Leiter International Performance Scale - Revised (Leiter-R)

    Forward Memory and Attention Sustained sub-tests of the Leiter International Performance Scale - Revised (Leiter-R), a cognitive assessment instrument for children and adolescents that is not language dependent was planned.

    Time frame: Baseline (Day 0) to Visit 3 (Week 10) or early termination

07

Results

Posted Apr 23, 2018
Limitations and caveats
This was a 10-week double blind placebo-controlled trial that was terminated early due to the results of a similarly-designed study showing it would be futile to continue this study.

Participant flow

Participant flow — Overall Study
MilestoneDonepezil HydrochloridePlacebo
Started53
Completed00
Not completed53
Withdrew: Study terminated by sponsor53

Outcome measures

PrimaryMean Change From Baseline in Vineland-II Adaptive Behavior Scale (VABS-II) Parent/Caregiver Rating Form (PCRF) Score Using Last Observation Carried Forward (LOCF)

Mean change from Baseline from Visit 1 (baseline) to Visit 3 (Week 10 or early termination) in VABS-11/PCRF, a sum of the 9 sub-domain v-scores (3 scores for each of the communication, daily living skills, and socialization domains) using last observation carried forward was planned.

Time frame:
Baseline (Day 0) to Visit 3 (Week 10) or at early termination

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Additional Analyses of the VABS-11/PCRF

Additional analyses of the VABS-II/PCRF were planned.

Time frame:
Baseline (Day 0) to Visit 3 (Week 10) or early termination

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER)

TOVER, a subject performance-based measure of expressive language function was planned.

Time frame:
Baseline (Day 0) to Visit 3 (Week 10) or early termination

No measurements were reported for this outcome.

SecondaryMean Change From Baseline if the Forward Memory and Attention Sustained Sub-tests of the Leiter International Performance Scale - Revised (Leiter-R)

Forward Memory and Attention Sustained sub-tests of the Leiter International Performance Scale - Revised (Leiter-R), a cognitive assessment instrument for children and adolescents that is not language dependent was planned.

Time frame:
Baseline (Day 0) to Visit 3 (Week 10) or early termination

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) and treatment emergent AEs (TEAEs) were collected from the time of screening (prior to start of study medication) until termination of the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil Hydrochloride0/5 (0%)0/5 (0%)2/5 (40%)
Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventDonepezil HydrochloridePlacebo
NauseaGastrointestinal disorders1/51/3
DiarrheaGeneral disorders1/51/3
Ear infectionInfections and infestations1/50/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Donepezil HydrochloridePlaceboTotal
Mean12.8 (11 to 16)15.0 (13 to 17)13.6 (11 to 17)
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil HydrochloridePlaceboTotal
Female112
Male426
08

Study locations

2 sites
  • Road Runner Research
    San Antonio, Texas 78258, United States
  • Neuroscience, Inc
    Herndon, Virginia 20170, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2008
First posted
Sep 17, 2008
Start
Sep 2008
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results first posted
Apr 23, 2018
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00754052
Lead sponsor
Eisai Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 17, 2008
Start date
Sep 2008
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Apr 23, 2018
Last update
Apr 23, 2018

Study contacts

Thomas McRae, MD
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion